Cognition Therapeutics rises on FDA support for late-stage trials of Alzheimer’s drug

** Shares of drug developer Cognition Therapeutics rise 16.4% to $1.28 in extended trading

** Cognition Therapeutics is developing an experimental pill called zervimesine to treat patients with Alzheimer’s disease

** CGTX says FDA agreed that Cognition can focus their studies on patients with mild-to-moderate Alzheimer’s who have certain blood test results, making it more likely the medicine will help them

** "One of the most important outcomes from the meeting was the FDA’s view that two six-month Phase 3 studies could support a new drug application for zervimesine" Lisa Ricciardi, president and CEO of Cognition Therapeutics says

** CGTX stock up 55.6% YTD